Althia, a Spanish biomedical company focused on personalized predictive oncology, has raised €3m in funding.
Backers include venture capital firm Inveready Group, CECU Inversiones, HSS and family office Reiman Inversiones SL.
The company will leverage the funding to strengthen the business line to initiate diagnostic services and treatment activity for cancer patients by single-dose
radiation therapy guided by image.
Formed in 2007 by Dr. Carlos Cordon-Cardo, Professor and Chairman of the Pathology Department at The Mount Sinai Hospital in New York (Scientific Vice
President), and Dr. Zvi Fuchs, Director of Champalimaud Centre for the Unknown at Lisbon, (Medical Vice President), supported by Santiago de Torres (President), and Isabel Lozano (Executive Vice President), Althia has three areas of activity including:
- Care in Diagnosis/Prognosis,
- Translational Research and
- SD-IGRT Treatment (currently being implemented).
The company has advanced diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid.